Monday Jan 30 | Theflyonthewall.com
Cytori receives approval from FDA to initiate U.S. cardiac cell therapy trial
Cytori Therapeutics has received an Investigational Device Exemption, IDE, approval from the U.S. FDA to begin the ATHENA trial.
Adipose Stem Cell Heart Attack Trial Data Published in Journal of the ...
The APOLLO trial was a 14-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial evaluating autologous ADRCs extracted with the Company's proprietary Celution System for the treatment of patients suffering from acute myocardial infarction.
European Scandal Could Help Cytori Therapeutics
Often, factors outside of a company's control can pound it into the ground or, alternatively, provide an unanticipated boost.
Healthcare Sector Review: Winning and Losing Stocks on Dec 30th
SIGA Technologies, Inc. : The shares closed at $2.52, up $0.23, or 10.04%, on the day.
Also on Topix